Tofogliflozin, an SGLT2 inhibitor, demonstrates excellent tolerability and significantly reduces the magnetic resonance imaging proton density fat fraction (MRI-PDFF) in patients with NAFLD and T2DM [199]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.